AlloVir gains as Gilead adds to stake

This post was originally published on this site

The value of the purchase was nearly $11 million. Gilead owns a total of 16,635,286 common shares following the purchase, representing a nearly 15% stake.

On June 21, AlloVir announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. All shares were sold by the company.